We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS. RESULTS OF LYMA‐101 TRIAL, A LYSA GROUP STUDY.
- Authors
Le Gouill, S.; Beldi‐Ferchiou, A.; Cacheux, V.; Salles, G.; Canioni, D.; Bodet‐Milin, C.; Alcantara, M.; Delwail, V.; Gastinne, T.; Thieblemont, C.; Maisonneuve, H.; Lamy de la Chapelle, T.; Oberic, l.; Bouabdallah, K.; Ribrag, V.; Delfau‐Larue, M.; Macintyre, E.; Hermine, O.
- Subjects
STEM cell transplantation; CANCER treatment; ANTIBODY-dependent cell cytotoxicity; HEMATOLOGICAL oncology; MANTLE cell lymphoma
- Publication
Hematological Oncology, 2019, Vol 37, p44
- ISSN
0278-0232
- Publication type
Article
- DOI
10.1002/hon.14_2629